A Novel Scheme for Optimal Control of a Nonlinear Delay Differential Equations Model to Determine Effective and Optimal Administrating Chemotherapy Agents in Breast Cancer

Author(s):
Hamidreza  RamezanpourHamidreza Ramezanpour1,*, S SetayeshiS Setayeshi1, ME AkbariME Akbari2
1Amirkabir University of Technology, Tehran, Iran
2Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran

International Journal of Cancer Management:Vol. 4, issue 4; e80750
Published online:Dec 30, 2011
Article type:Research Article
Received:May 28, 2011
Accepted:Aug 15, 2011
How to Cite:Ramezanpour H, Setayeshi S, Akbari M. A Novel Scheme for Optimal Control of a Nonlinear Delay Differential Equations Model to Determine Effective and Optimal Administrating Chemotherapy Agents in Breast Cancer. Int J Cancer Manag. 2011;4(4):e80750. doi:

Abstract

Fulltext

The Full text is available in PDF.

Similar Articles

12
May
2018

Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients After Neoadjuvant Chemotherapy: A Comparative Matched Study

Amir Shahram Yousefi Kashi,
Rezvan Montazeri,
Afshin Rakhsha

Yousefi Kashi AS, Montazeri R, Rakhsha A. Clinical Outcome and Prognostic Factors in Iranian Breast Cancer Patients After Neoadjuvant Chemotherapy: A Comparative Matched Study. Int J Cancer Manag. 2018;11(5):e67739. doi: https://doi.org/10.5812/ijcm.67739

25
Apr
2026

Breast Tumor Response & Axillary Clearance After Neoadjuvant Chemotherapy

Mahdis Bayat,
Hossein Hatami,
Mohammad Esmaeil Akbari

Bayat M, Hatami H, Akbari ME. Breast Tumor Response & Axillary Clearance After Neoadjuvant Chemotherapy. Int J Cancer Manag. 2026;19(1):e170019. doi: https://doi.org/10.5812/ijcm-170019

12
May
2018

Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study

Asiie Olfatbakhsh,
Hoda Tafazzoli-Harandi,
Safa Najafi,
Esmat Al Sadat Hashemi,
Fateme Sari,
Parisa Mokhtari Hesari
,et al.

Olfatbakhsh A, Tafazzoli-Harandi H, Najafi S, Hashemi EAS, Sari F, et al. Factors Impacting Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Study. Int J Cancer Manag. 2018;11(5):e60098. doi: https://doi.org/10.5812/ijcm.60098

20
Dec
2023
Int J Cancer Manag

Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review

Mohammad Akbari,
Maryam Seyednezhad,
Saeed Heidari,
Mohammad Moradi-joo

Akbari M, Seyednezhad M, Heidari S, Moradi-joo M. Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review. Int J Cancer Manag. 2023;16(1):e142814. doi: https://doi.org/10.5812/ijcm-142814

30
Dec
2024
J Inflamm Dis

Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients

Mehdi Cheraghi,
Ensiyeh Bahadoran,
Maryam Masoomi,
Navid Mohammadi

Cheraghi M, Bahadoran E, Masoomi M, Mohammadi N. Pilot Study Comparing Epirubicin, Oxaliplatin, Capecitabine (EOX) and Docetaxel, Cisplatin, and 5-Fluorouracil (TCF) Regimens in Neoadjuvant Chemotherapy for Gastric Cancer Patients. J Inflamm Dis. 2024;28(4):e154396. doi: https://doi.org/10.69107/jid-154396

Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC 

Search Relations

Author(s):

Related Articles